Mobocertinib: Mechanism of action, clinical, and translational science

Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Michael J. Hanley (Author), D. Ross Camidge (Author), Robert J. Fram (Author), Neeraj Gupta (Author)
Format: Knjiga
Izdano: Wiley, 2024-03-01T00:00:00Z.
Teme:
Online dostop:Connect to this object online.
Oznake: Označite
Brez oznak, prvi označite!

Internet

Connect to this object online.

3rd Floor Main Library

Podrobnosti zaloge 3rd Floor Main Library
Signatura: A1234.567
Kopija 1 Prosto